Role of caspase 8 as a determinant in chemosensitivity of p53-mutated head and neck squamous cell carcinoma cell lines

Journal of Medical and Dental Sciences

Volumn 53, Issue 1, 2006, Pages 57-66

  Kaneda, Yoshimasa ^a   Shimamoto, Hiroaki ^a   Matsumura, Kouji ^b   Arvind, Ramanathan ^a   Zhang, Shengliang ^a   Sakai, Eiki ^c   Omura, Ken ^a   Tsuchida, Nobuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Akt; Caspase 8; Etoposide; Head and neck squamous cell carcinoma; TRAIL

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CASP8 PROTEIN, HUMAN; CASPASE; CASPASE 8; CHROMONE DERIVATIVE; CISPLATIN; ETOPOSIDE; FLUOROURACIL; MEMBRANE PROTEIN; MORPHOLINE DERIVATIVE; PROTEIN KINASE B; PROTEIN P53; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HEAD AND NECK TUMOR; HUMAN; METABOLISM; MUTATION; PHOSPHORYLATION; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SQUAMOUS CELL; CASPASE 8; CASPASES; CELL LINE, TUMOR; CHROMONES; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MEMBRANE GLYCOPROTEINS; MORPHOLINES; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645668984     PISSN: 13428810     EISSN: 13428810     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics. CA Cancer J Clin 2002;52:23-47.
2. Longley DB, Johnston PG. Molecular mechanism of drug resistance. J Pathol 2005;205:275-292.
3. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003;10:431-442.
4. Blagosklonny MV. p53:an ubiquitous target of anticancer drugs. Int. J. Cancer 2003;98:161-166.
5. Fritzsche C, Zeller G, Knaup KX, et al. No anti-apoptotic effects of single copies of mutant p53 genes in drug-treated tumor cells. Anticancer Drugs 2004;15:679-88.
6. Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev 2004;23:237-257.
7. Tsang WP, Ho FY, Fung KP, et al. p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer 2004;114:331-336
8. Sheikh MS, Fornace AJ Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000;14:1509-1513.
9. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
10. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657.
11. Luo J, Manning BD, Cantley LC. Targeting the PI3K-AKT pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-262.
12. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987;84:5034-5037.
13. Datta SR, Brunet A, Greenberb ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2927.
14. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2002;61:3986-3997.
15. Kim D, Dan HC, Park S, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005;10:975-984.
16. Cardone M H, Roy N, Stennicke H R, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science (Wash. DC) 1998;282:1318-1321.
17. del Peso L, Gonzalez-Garcia M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (Wash. DC) 1997;278:687-689.
18. Altucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia is mediated by paracrine action of tumor-selective death ligand: TRAIL. Nat Med 2001;7:680-686.
19. Pitti R M, Marsters S A, Ruppert S, et al. Induction of apoptosis by Apo2 ligand, a new member of the tumor necrosis factor receptor family. J Biol Chem 1996;271:12687-12690.
20. Ashkenazi A, Dixit V M. Death receptors: signaling and modulation. Science (Wash. DC) 1998;281:1305-1308.
21. Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001;6:171-177.
22. Tadokoro K, Ueda M, Ohshima T, et al. Activation of oncogenes in human oral cancer cells: a novel codon 13 mutation of c-H-ras-1 and concurrent amplifications of c-erbB-1 and c-myc. Oncogene 1989;4:499-505.
23. Sakai E, Rikimaru K, Ueda M, et al. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer 1992;52:867-872.
24. Rikimaru K, Tadokoro K, Yamamoto T, et al. Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck. Head Neck 1992;14:8-13.
25. Matsumura K. Detection of DNA amplifications and deletions in oral squamous cell carcinoma cell lines by comparative genomic hybridization (CGH) (in Japanese, English abstract). Kokubyo Gakkai Zasshi 1995;62:513-531.
26. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992;7:927-933.
27. Zhang S, Fukushi M, Hashimoto S, et al. A new ERK2 binding protein, Naf1, attenuates the EGF/ERK2 nuclear signaling. Biochem Biophys Res Commun 2002;297:17-23.
28. Vlahos CJ, Matter WF, Hui KY, et al. A specific inhibitor of phosphatidylinositol 3-kinase 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyrean-4-one (LY294002). J Biol Chem 1994;269:5241-5248.
29. Bortul R, Tazzari PL, Cappellini A, et al. Constitutively active AKT1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kB activation and c-FLIP(L) up-regulation. Leukemia 2003;17:379-389.
30. Li JH, Pober JS. The cathepsin B death pathway contributes to TNF plus IFN-gamma-mediated human endothelial injury. J Immunol. 2005;175:1858-1866.
31. Madge LA, Li JH, Choi J, et al. Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis. J Biol Chem. 2003;278:21295-306.
32. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
33. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003;22:3205-3212.
34. von Haefen C, Wieder T, Essmann F, et al. Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 2003;22:2236-2247.
35. Shivapurkar N, Reddy J, Matta H, et al. Loss of expression of death inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 2002;21:8510-8514.
36. Casciano I, Banelli B, Croce M, et al. Caspase-8 gene expression in neuroblastoma. Ann NY Acad Sci 2004;1028:157-167.
37. Soung YH, Lee JW, Kim SY, et al. Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225-1226delTG in hepatocellular carcinomas. Oncogene 2004;24:141-147.
38. Toyozumi Y, Arima N, Izumaru S, et al. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma. HEp-2 cells. Int J Oncol 2004;25:721-728.
39. Sohn D, Schulze-Osthoff K, Janicke RU. Caspase-8 can be activated by interchain proteolysis without receptor-triggered dimerization during drug-induced apoptosis. J Biol Chem 2005;280:5267-5273